Ciprofloxacin and Tinidazole Induced Steven Johnson Syndrome

Technical Summary: Ciprofloxacin and Tinidazole Induced Stevens-Johnson Syndrome

Problem Statement
Stevens–Johnson Syndrome (SJS) is a rare, life-threatening mucocutaneous adverse drug reaction (ADR) characterized by epidermal necrosis and mucosal involvement, with an estimated incidence of 2–7 cases per million annually. While the condition is most frequently triggered by sulfonamides, anticonvulsants, and NSAIDs, the association with fluoroquinolones (specifically ciprofloxacin) and nitroimidazoles (specifically tinidazole) is considered rare and clinically under-recognized. The primary challenge in managing such cases involves the rapid identification of the offending agents, the exclusion of alternative etiologies (such as infections or other drug classes), and the implementation of immediate supportive care to prevent progression to Toxic Epidermal Necrolysis (TEN) or systemic failure, particularly in patients with significant comorbidities.

Methodology
This study presents a single-case report of a 65-year-old female patient with a complex medical history, including Type 2 Diabetes Mellitus, Chronic Kidney Disease (CKD), and Hypertension. The patient presented with a 5-day history of painful oral erosions and erythematous cutaneous lesions on the palms, soles, and lower limbs.

• Diagnostic Approach: The diagnosis was established clinically based on a strong temporal relationship between the onset of symptoms (3–5 days post-initiation) and the administration of ciprofloxacin and tinidazole for a presumed gastrointestinal/urinary tract infection. The diagnosis was supported by the exclusion of alternative causes and the characteristic mucocutaneous presentation. A skin biopsy was not performed due to patient refusal and acute instability.
• Intervention Strategy: The management protocol involved the immediate discontinuation of the suspected drugs. The patient was admitted to a monitored setting (Medical ICU) and treated with a multidisciplinary approach including:
  • Pharmacological Therapy: Systemic corticosteroids (Intravenous Hydrocortisone 200mg and Decadron), antihistamines (Intravenous/Intramuscular Avil and oral Allegra) for pruritus, and topical anesthetics (Mucopain Gel) and antiseptics (Chlorhexidine) for mucosal care.
  • Supportive Care: Aggressive fluid and electrolyte management to address hypovolemia and renal function, nutritional assessment, and temperature control.
  • Monitoring: Daily assessment of vital signs, laboratory parameters (including renal function, electrolytes, and inflammatory markers), and wound progression.

Key Results
The clinical course demonstrated a halt in disease progression within 48–72 hours of initiating the withdrawal of offending agents and the commencement of corticosteroid therapy.

• Clinical Outcome: The patient experienced gradual resolution of mucocutaneous lesions. While the patient developed steroid-induced hyperglycemia and hyponatremia, these were managed through electrolyte replacement and insulin therapy.
• Discharge: The patient was stabilized and discharged with a recommendation for lifelong avoidance of both ciprofloxacin and tinidazole.
• Laboratory Findings: Initial labs indicated renal impairment (Creatinine 5.8 mg/dL, Urea 128 mg/dL) and anemia, which were consistent with the patient's history of CKD and the acute stress of the reaction. Viral markers (HIV, HBsAg, HCV) were negative, ruling out infectious triggers.

Significance and Claims
The authors assert that this case is clinically noteworthy because ciprofloxacin and tinidazole are uncommon triggers for SJS, with fluoroquinolones implicated in less than 1% of reported SJS/TEN cases and tinidazole having even fewer documented associations in the literature.

The paper claims the following significance:

1. Vigilance for Rare Triggers: It highlights the necessity for clinicians to consider fluoroquinolones and nitroimidazoles as potential causes of acute mucocutaneous reactions, even in the absence of a classic "high-risk" drug history.
2. Importance of Early Recognition: The case underscores that prompt recognition and immediate withdrawal of the suspected drug are critical for halting disease progression and improving prognosis.
3. Multidisciplinary Management: It reinforces the role of individualized supportive care and the critical function of clinical pharmacists in identifying offending agents, optimizing therapy, and preventing future triggers in patients with multiple comorbidities.

The authors conclude that while the pathophysiology involves a Type IV hypersensitivity reaction, the management relies heavily on supportive care and the timely cessation of the causative agent, rather than a single definitive pharmacological cure. The report serves as a cautionary addition to the literature regarding the spectrum of antimicrobial-induced SJS.